Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan

REFERENCES

1. 1.↵
   1. Emery P,
   2. Keystone E,
   3. Tony HP,
   4. Cantagrel A,
   5. van Vollenhoven R,
   6. Sanchez A,
   7. et al.

   IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Genovese MC,
   2. McKay JD,
   3. Nasonov EL,
   4. Mysler EF,
   5. da Silva NA,
   6. Alecock E,
   7. et al.

   Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Jones G,
   2. Sebba A,
   3. Gu J,
   4. Lowenstein MB,
   5. Calvo A,
   6. Gomez-Reino JJ,
   7. et al.

   Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88–96.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Kremer JM,
   2. Blanco R,
   3. Brzosko M,
   4. Burgos-Vargas R,
   5. Halland AM,
   6. Vernon E,
   7. et al.

   Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609–21.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Smolen JS,
   2. Beaulieu A,
   3. Rubbert-Roth A,
   4. Ramos-Remus C,
   5. Rovensky J,
   6. Alecock E,
   7. et al.

   Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Nishimoto N,
   2. Hashimoto J,
   3. Miyasaka N,
   4. Yamamoto K,
   5. Kawai S,
   6. Takeuchi T,
   7. et al.

   Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162–7.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Nishimoto N,
   2. Miyasaka N,
   3. Yamamoto K,
   4. Kawai S,
   5. Takeuchi T,
   6. Azuma J,
   7. et al.

   Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12–9.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Schiff MH,
   2. Kremer JM,
   3. Jahreis A,
   4. Vernon E,
   5. Isaacs JD,
   6. van Vollenhoven RF

   . Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Koike T,
   2. Harigai M,
   3. Inokuma S,
   4. Ishiguro N,
   5. Ryu J,
   6. Takeuchi T,
   7. et al.

   Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 2014;41:15–23.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Nakajima A,
    2. Inoue E,
    3. Tanaka E,
    4. Singh G,
    5. Sato E,
    6. Hoshi D,
    7. et al.

    Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 2010;39:360–7.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Genovese MC,
    2. Rubbert-Roth A,
    3. Smolen JS,
    4. Kremer J,
    5. Khraishi M,
    6. Gomez-Reino J,
    7. et al.

    Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768–80.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Smitten AL,
    2. Simon TA,
    3. Hochberg MC,
    4. Suissa S

    . A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Yamada T,
    2. Nakajima A,
    3. Inoue E,
    4. Tanaka E,
    5. Taniguchi A,
    6. Momohara S,
    7. et al.

    Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 2011;31:1487–92.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Harigai M,
    2. Nanki T,
    3. Koike R,
    4. Tanaka M,
    5. Watanabe K,
    6. Komano Y,
    7. et al.

    Biological agents in rheumatoid arthritis and risk of malignancy — results from the nation-wide cohort study in Japan [abstract]. Arthritis Rheum 2011;63 Suppl:S41.

    OpenUrl
15. 15.↵
    1. Gout T,
    2. Ostor AJ,
    3. Nisar MK

    . Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011;30:1471–4.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Barnabe C,
    2. Martin BJ,
    3. Ghali WA

    . Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522–9.

    OpenUrlCrossRef
17. 17.↵
    1. Westlake SL,
    2. Colebatch AN,
    3. Baird J,
    4. Kiely P,
    5. Quinn M,
    6. Choy E,
    7. et al.

    The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2010;49:295–307.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Takeuchi T,
    2. Tatsuki Y,
    3. Nogami Y,
    4. Ishiguro N,
    5. Tanaka Y,
    6. Yamanaka H,
    7. et al.

    Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189–94.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Koike T,
    2. Harigai M,
    3. Inokuma S,
    4. Ishiguro N,
    5. Ryu J,
    6. Takeuchi T,
    7. et al.

    Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011;21:343–51.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Koike T,
    2. Harigai M,
    3. Ishiguro N,
    4. Inokuma S,
    5. Takei S,
    6. Takeuchi T,
    7. et al.

    Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol 2014;24:390–8.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Nishimoto N,
    2. Miyasaka N,
    3. Yamamoto K,
    4. Kawai S,
    5. Takeuchi T,
    6. Azuma J

    . Longterm safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580–4.

    OpenUrlAbstract/FREE Full Text